Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

Simply Cellceutix;

Share Statistics
Avg Vol (3 month)3: 219,240
Avg Vol (10 day)3: 108,217
Shares Outstanding5: 119.93M
Float: 75.37M
% Held by Insiders1: 34.18%
http://finance.yahoo.com/q/ks?s=CTIX+Key+Statistics

============================
Sox posted:

CTIX Potential Catalysts and Past Milestones

Q2 2016 Potential Catalysts

- P top-line data (Phase 2)
- B-OM interim data (Phase 2)
- K top-line data (Phase 1)
- Start of B-ABSSSI (Phase 3)
- Start of B-UP (Phase 2, proof of concept)
- Start of K-ovarian (Phase 2)
- Fast track designation for B-ABSSSI
- ASM Microbe presentations (June 19-20)

Past Milestones

- QIDP designation for B-ABSSSI
- Fast track designation for B-OM
- Orphan drug designation for K-ovarian cancer
- Orphan drug designation for K-pancreatic cancer
- Orphan drug designation for K-retinoblastoma
- Rare pediatric disease designation for K-retinoblastoma
- B-ABSSSI positive Phase 2b top-line & bottom line data
- Completion of cohort 11 (750 mg/m2)
- K positive primary outcome (Phase 1)
- P positive primary outcome (Phase 1)
- Stable formulation of B at room temperature
- MTA extension on testing B in implanted devices

Clinical Trials

1. P (Phase 1, completed): https://clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=1
2. P (Phase 2, not recruiting): https://clinicaltrials.gov/ct2/show/NCT02101216?term=cellceutix&rank=2
3. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=3
4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT02052388?term=cellceutix&rank=4
5. K (Phase 1, completed): https://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=5

Abbreviations

K – Kevetrin
B – Brilacidin
P – Prurisol
ABSSSI – acute bacterial skin and skin structure infections
OM – oral mucositis
UP – ulcerative proctitis
QIDP – qualified infectious disease product
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121674017

==========================================



Product Pipeline

http://cellceutix.com/pipeline/#sthash.4g5edEap.dpuf

==========================================


http://www.sec.gov/Archives/edgar/data/1355250/000147793216008473/ctix_10q.htm

Cellceutix Corporation was incorporated on August 1, 2005, in the State of Nevada. On December 6, 2007, the Company acquired Cellceutix Pharma, Inc., a privately owned corporation formed under the laws of the State of Delaware on June 20, 2007. Following the acquisition, the Company changed its name to Cellceutix Corporation. Cellceutix Corporation dissolved its subsidiary Cellceutix Pharma, Inc. in 2014.


Now go back to the beginning of this post...

Shares Outstanding5: 119.93M
Float: 75.37M

I wonder how many get this picture. The Kevetrin trial alone with the staff involved in moving this forward, regardless of how long phase 1 has taken, and we're still waiting for full data. And at the same time, Kevetrin is moving onto further trials even and potential grant support. Brilaciden is looking very good as well. I'm not doing any justice leaving that potential out. As well as prurisol and the other pre clinicals.

Product Pipeline Oncology Kevetrin™ Brilacidin-OM Dermatology Prurisol™ Antibiotics Brilacidin Brilacidin-Ocular Brilacidin-Otic Gram Negative Bacteria Candidiasis Diabetic Foot Infections/Ulcers - See more at: http://cellceutix.com/pipeline/#sthash.4g5edEap.dpuf


Some may call this gambling. I don't. I review probably more than 30 companies a week, even if only for a few minutes. Not just in the bio sector either. Though start up bio's do pose the highest risk, I don't see the same potential with other start up bio's as I do here.

It doesn't take that much time to flip through the pages of the filing and the trials to date to see how the CEO has managed to keep dilution and funding under control and still keep things moving.

Just a little patience.


In Reply to 'DaubersUP'

I am a huge gambler. I love Vegas and also sports betting. This CTIX bet is prime at this point:

People have to realize the gains that could be triggered by much of what the SA piece described. However if it fails we know B is almost a certainty so even if the sp dives to 1.20 levels or even lower yo know you will get your money back probably by year end plus some... So why not bet now?!?!? One could make a 10x gain in the next 2-3 months if p is great!

Aimo